Literature DB >> 6654895

Structure of human erythrocyte spectrin. I. Isolation of the alpha-I domain and its cyanogen bromide peptides.

D W Speicher, G Davis, P D Yurchenco, V T Marchesi.   

Abstract

The alpha-I domain of human erythrocyte spectrin was produced by a mild tryptic digestion of the intact molecule and purified by a single step affinity chromatography procedure using a monoclonal antibody. A tryptic peptide representing the alpha-I domain, which migrated on polyacrylamide gels as an 80,000-dalton peptide, was subjected to automated Edman-Begg degradation. Products from automated sequencing were identified by reverse-phase high performance liquid chromatography. Two smaller proteolytic products of the alpha-I domain (T74 and T50) were also subjected to automated sequence analysis. CNBr cleavage of the alpha-I domain produced nine unique peptides which were separated by gel filtration on a high performance liquid chromatograph. Peptides were further purified by reverse-phase chromatography and characterized by amino acid analysis. Partial sequences were determined by automated NH2-terminal sequence analysis. A single aspartate-proline bond, which was partially hydrolyzed during the cyanogen bromide cleavage reaction, was also identified. These sequence data include the first 86 residues of the alpha-I domain, and the spectrin oligomer binding site has been tentatively localized within the first 39 residues. The sequence of 293 residues of a total 633 residues in the alpha-I domain is presented and represents the first structural information for this protein.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6654895

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Flexibility of the alpha-spectrin N-terminus by EPR and fluorescence polarization.

Authors:  L Cherry; L W Fung; N Menhart
Journal:  Biophys J       Date:  2000-07       Impact factor: 4.033

2.  Two elliptocytogenic alpha I/74 variants of the spectrin alpha I domain. Spectrin Culoz (GGT----GTT; alpha I 40 Gly----Val) and spectrin Lyon (CTT----TTT; alpha I 43 Leu---Phe).

Authors:  L Morlé; A F Roux; N Alloisio; B Pothier; J Starck; L Denoroy; F Morlé; R C Rudigoz; B G Forget; J Delaunay
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

3.  Mutant forms of spectrin alpha-subunits in hereditary elliptocytosis.

Authors:  S L Marchesi; J T Letsinger; D W Speicher; V T Marchesi; P Agre; B Hyun; G Gulati
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

4.  Abnormal oxidant sensitivity and beta-chain structure of spectrin in hereditary spherocytosis associated with defective spectrin-protein 4.1 binding.

Authors:  P S Becker; J S Morrow; S E Lux
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

5.  Remarkable homology among the internal repeats of erythroid and nonerythroid spectrin.

Authors:  C S Birkenmeier; D M Bodine; E A Repasky; D M Helfman; S H Hughes; J E Barker
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

6.  Detection and characterization of a mouse alpha-spectrin cDNA clone by its expression in Escherichia coli.

Authors:  L Cioe; P Curtis
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

7.  Amino acid sequence of the plasma membrane ATPase of Neurospora crassa: deduction from genomic and cDNA sequences.

Authors:  K M Hager; S M Mandala; J W Davenport; D W Speicher; E J Benz; C W Slayman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

8.  A map of photolytic and tryptic cleavage sites on the beta heavy chain of dynein ATPase from sea urchin sperm flagella.

Authors:  G Mocz; W J Tang; I R Gibbons
Journal:  J Cell Biol       Date:  1988-05       Impact factor: 10.539

9.  Primary structure of the brain alpha-spectrin.

Authors:  V M Wasenius; M Saraste; P Salvén; M Erämaa; L Holm; V P Lehto
Journal:  J Cell Biol       Date:  1989-01       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.